Progestin-primed Ovarian Stimulation With Clomiphene Citrate Compared With the Standard Progestin-primed Ovarian Stimulation in Various Aged Women With Diminished Ovarian Reserve: a Retrospective Study

Background: Clomiphene citrate (CC) supplementation in the progestin-primed ovarian stimulation (PPOS) protocol effectively alleviated profound pituitary suppression from progestin administration and reduced the gonadotropin (Gn) dose in the population of women with normal-ovarian-reserve or polycystic ovarian syndrome. Limited data are available about the role of CC in PPOS for women with diminished ovarian reserve (DOR). This study aimed to compare the efficiency of the PPOS protocol with CC supplementation and the standard PPOS protocol for various aged women with DOR.Methods: A total of 364 patients with DOR were recruited for this retrospective cohort study. They were divided into subgroups based on female age, ≤35 years and ＞35 years. The clinical characteristics and outcome were compared between the groups in subgroups.Results: In all patients with DOR, the PPOS protocol with CC supplementation was associated with a lower percentage of women with profound pituitary suppression (0.0% vs 18.6%, P ＜0.001 and 1.3% vs 11.0%, P ＝0.002) and a higher mean luteinizing hormone (LH) level during controlled ovarian stimulation (COS) than the standard PPOS protocol (P ＜0.05＝. In young women with DOR, more number of high-quality cleavage-stage embryos (1.96 vs. 1.38, P ＝0.018) was achieved in the PPOS protocol with CC supplementation. In elderly women with DOR, PPOS protocol with CC supplementation led to an increase in the incidence of LH levels above 10 IU/L on the trigger day (12.7% vs. 4.9%, P ＝0.028) and decrease in the rate of oocyte maturation (84.7% vs. 89.9%, P ＝0.034) compared to the standard PPOS protocol. No significant differences were observed in the Gn duration, total dosage of Gn, and pregnancy outcomes between the groups. Conclusions: CC is an effective adjuvant to alleviate pituitary suppression in the PPOS protocol. For young women with DOR, CC supplementation has a positive impact on the number of high-quality embryos in PPOS protocol. However, elderly patients with DOR would be at risk of developing premature LH surge and poor oocyte maturation rate after the PPOS protocol with CC supplementation was applied.

[1]  Beihong Zheng,et al.  A meta-analysis of the efficacy of progestin-primed ovarian stimulation with medroxyprogesterone acetate in ovulation induction in poor ovarian responders. , 2020, Journal of gynecology obstetrics and human reproduction.

[2]  P. Ghosh,et al.  Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization , 2020, Journal of human reproductive sciences.

[3]  P. Humaidan,et al.  Low LH Level on the Day of GnRH Agonist Trigger Is Associated With Reduced Ongoing Pregnancy and Live Birth Rates and Increased Early Miscarriage Rates Following IVF/ICSI Treatment and Fresh Embryo Transfer , 2019, Front. Endocrinol..

[4]  Lei Jia,et al.  Different progestin-primed ovarian stimulation protocols in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: an analysis of 1188 cycles , 2019, Archives of Gynecology and Obstetrics.

[5]  W. He,et al.  Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes and suboptimal pregnancy outcomes compared with the standard progestin-primed ovarian stimulation in infertile women with polycystic ovarian syndrome , 2018, Reproductive Biology and Endocrinology.

[6]  W. He,et al.  Progestin‐primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: A prospective randomized controlled trial , 2018, Clinical endocrinology.

[7]  Xuefeng Lu,et al.  The pregnancy outcome of progestin‐primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial , 2017, BJOG : an international journal of obstetrics and gynaecology.

[8]  S. Daya,et al.  Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection. , 2016, Fertility and sterility.

[9]  F. Ubaldi,et al.  A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. , 2016, Fertility and sterility.

[10]  Z. Shoham,et al.  Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. , 2015, Fertility and sterility.

[11]  M. Hickey,et al.  What is the "ovarian reserve"? , 2015, Fertility and sterility.

[12]  Z. Rosenwaks,et al.  Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. , 2014, Fertility and sterility.

[13]  M. J. de los Santos,et al.  A multicenter prospective study to assess the effect of early cleavage on embryo quality, implantation, and live-birth rate. , 2014, Fertility and sterility.

[14]  S. Sunkara,et al.  Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. , 2014, Human reproduction update.

[15]  L. Engmann,et al.  In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle. , 2011, Fertility and sterility.

[16]  D. Barad,et al.  The impact of luteinizing hormone in assisted reproduction: a review , 2007, Current opinion in obstetrics & gynecology.

[17]  G. Ruvolo,et al.  Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. , 2007, Fertility and sterility.

[18]  G. Emons,et al.  Effects of estradiol and some antiestrogens (Clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture , 2005, Archives of gynecology.

[19]  P. Devroey,et al.  Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. , 2002, Fertility and sterility.

[20]  S. Hillier,et al.  Gonadotropic control of ovarian follicular growth and development , 2001, Molecular and Cellular Endocrinology.

[21]  L. Westergaard,et al.  Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. , 2000, Human reproduction.

[22]  J. Fenwick,et al.  Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. , 1998, Human reproduction.

[23]  S. Hillier.  Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. , 1994, Human reproduction.

[24]  J. Liu,et al.  Evidence for a hypothalamic site of action of clomiphene citrate in women. , 1985, The Journal of clinical endocrinology and metabolism.

[25]  E. Adashi,et al.  Clomiphene citrate: mechanism(s) and site(s) of action--a hypothesis revisited. , 1984, Fertility and sterility.

[26]  L. Wildt,et al.  On the site of action of progesterone in the blockade of the estradiol-induced gonadotropin discharge in the rhesus monkey. , 1981, Endocrinology.

[27]  D. Dierschke,et al.  Blockade by progesterone of estrogen-induced LH and FSH release in the rhesus monkey. , 1973, Endocrinology.